Literature DB >> 32085521

Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience.

Candace R Lewis1,2, Katrin H Preller2, B Blair Braden3, Cory Riecken3, Franz X Vollenweider2.   

Abstract

Psilocybin is the psychoactive compound of mushrooms in the psilocybe species. Psilocybin directly affects a number of serotonin receptors, with highest affinity for the serotonin 2A receptor (5HT-2Ar). Generally, the effects of psilocybin, and its active metabolite psilocin, are well established and include a range of cognitive, emotional, and perceptual perturbations. Despite the generality of these effects, there is a high degree of inter-individual variability in subjective psilocybin experiences that are not well understood. Others have shown brain morphology metrics derived from magnetic resonance imaging (MRI) can predict individual drug response. Due to high expression of serotonin 2A receptors (5HT-2Ar) in the cingulate cortex, and its prior associations with psilocybin, we investigate if cortical thickness of this structure predicts the psilocybin experience in healthy adults. We hypothesized that greater cingulate thickness would predict higher subjective ratings in sub-scales of the Five-Dimensional Altered State of Consciousness (5D-ASC) with high emotionality in healthy participants (n = 55) who received oral psilocybin (either low dose: 0.160 mg/kg or high dose: 0.215 mg/kg). After controlling for sex, age, and using false discovery rate (FDR) correction, we found the rostral anterior cingulate predicted all four emotional sub-scales, whereas the caudal and posterior cingulate did not. How classic psychedelic compounds induce such large inter-individual variability in subjective states has been a long-standing question in serotonergic research. These results extend the traditional set and setting hypothesis of the psychedelic experience to include brain structure metrics.

Entities:  

Keywords:  5HT2Ar; cingulate; emotion; psilocybin

Year:  2020        PMID: 32085521     DOI: 10.3390/biomedicines8020034

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  5 in total

Review 1.  Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.

Authors:  Jacob S Aday; Alan K Davis; Cayla M Mitzkovitz; Emily K Bloesch; Christopher C Davoli
Journal:  ACS Pharmacol Transl Sci       Date:  2021-03-05

2.  Dose-response relationships of psilocybin-induced subjective experiences in humans.

Authors:  Tim Hirschfeld; Timo T Schmidt
Journal:  J Psychopharmacol       Date:  2021-03-04       Impact factor: 4.153

Review 3.  Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.

Authors:  John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane
Journal:  Front Psychiatry       Date:  2021-12-17       Impact factor: 4.157

Review 4.  Psilocybin for Treating Psychiatric Disorders: A Psychonaut Legend or a Promising Therapeutic Perspective?

Authors:  Maurizio Coppola; Francesco Bevione; Raffaella Mondola
Journal:  J Xenobiot       Date:  2022-02-07

5.  A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.

Authors:  Niloufar Pouyan; Zahra Halvaei Khankahdani; Farnaz Younesi Sisi; Yena Lee; Joshua D Rosenblat; Kayla M Teopiz; Leanna M W Lui; Mehala Subramaniapillai; Kangguang Lin; Flora Nasri; Nelson Rodrigues; Hartej Gill; Orly Lipsitz; Bing Cao; Roger Ho; David Castle; Roger S McIntyre
Journal:  CNS Drugs       Date:  2022-09-12       Impact factor: 6.497

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.